Company profile
Aligos Therapeutics, Inc.
NASDAQ: ALGS · Healthcare · Biotechnology
#783 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
48DFH 38DQ 62GM —SS 48
v0.1 · 55/100 weight · provisional
↑ filing timeliness, balance-sheet leverage · ↓ operating margin, revenue growth (YoY)
Methodology →Revenue TTM
$31.5M
Rev growth YoY (TTM)
+893.0%
Net income (FY)
-$24.2M
Employees
82
as of 2026-08-20
Market cap
$42.6M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.2M$2.2M2025
Net income-$24.2M-$24.2M2025
Operating income-$88.0M-$88.0M2025
Total assets$88.5M$88.5M2025
Liabilities$35.0M$35.0M2025
Equity$53.5M$53.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aligos Therapeutics, Inc.’s revenue?
Aligos Therapeutics, Inc. booked $2.2M in FY2025 revenue, contracting 39% year over year — slower than 79% of Healthcare companies we track, at a -1106.7% net margin.
Peers · Healthcare
Femasys Inc.41DAdynxx, Inc.——Horizon Space Acquisition II Corp.——American Mobile Dental Corp.——Endexx Corporation——BNB Plus Corp.33DNeighbors
San Mateo →Key facts
CEOLawrence Blatt
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ALGS
Employees82
IPO date2020-10-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.